Sandoz Canada receives Health Canada approval to launch two oncology biosimilars: Ziextenzo® and Riximyo®

Sandoz Canada receives Health Canada approval to launch two oncology biosimilars: Ziextenzo® and Riximyo®

Ziextenzo® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-neoplastic drugs.Riximyo® is indicated to treat non-Hodgkin’s lymphoma and chronic lymphocytic leukemia and rheumatoid arthritis.These two approvals mark an important milestone for Sandoz Canada, bringing its biosimilars into oncology at a time when its biopharmaceutical portfolio already included products in immunology and endocrinology.BOUCHERVILLE, Quebec, June 09, 2020 (GLOBE NEWSWIRE) — Sandoz Canada Inc., a division of Novartis AG, announced today that Health Canada has approved Ziextenzo® (pegfilgrastim, reference biologic drug: Neulasta®) and Riximyo® (rituximab, reference biologic drug: Rituxan®) for marketing in Canada.Sandoz Canada received a Notice of Compliance from Health Canada on April 21, 2020, for the use of Ziextenzo® to reduce the incidence of febrile neutropenia, one of the most serious side effects of chemotherapy. Riximyo® was approved on April 28, 2020, to treat non-Hodgkin’s lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis.Neutropenia is a decrease in the number of neutrophils, a type of white blood cell, which predisposes the body to infections and prevents it from fighting them¹.According to statistics published by the Canadian Cancer Society², in 2019 an estimated 21,000 Canadians received a blood cancer diagnosis, which makes up approximately 10% of all cancer diagnoses and includes non-Hodgkin’s lymphoma (10,000) and leukemia (6,700). Survival rates for blood cancers have increased over the years, but they still caused the deaths of 7,200 Canadians in 2016, according to a report released by The Leukemia & Lymphoma Society of Canada³.
CBJ Newsmakers

Recommended
Thrive Cannabis Receives Extract Sales License from Health CanadaGolden Predator Enhances Brewery Creek Team; Expands Focus on Mine Development Planning